Add-on perampanel in Lance–Adams syndrome

Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Epilepsy Behav Case Rep
Egile Nagusiak: Steinhoff, Bernhard J., Bacher, Matthias, Kurth, Christoph, Staack, Anke M., Kornmeier, Reinhold
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2016
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4939387/
https://ncbi.nlm.nih.gov/pubmed/27437182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebcr.2016.05.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak